Dr Niman: This was released by Chiron themselves, so I think it would clinch it.
Oxford, UK, 17 August 2004 - Chiron Vaccines, part of California-based Chiron Corporation (NASDAQ: CHIR), today announced that it has won a further contract from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the US National Institutes of Health (NIH), to produce an investigational vaccine designed to protect against a potential pandemic-like strain of influenza. This H9N2 strain, along with the H5N1 avian strain that circulated in Asia last winter, is one of many subtypes of influenza virus that does not usually infect humans, and to which people have no immunity. Consequently, if it were to transmit from person to person the virus could result in a global outbreak of influenza, commonly called a pandemic.
<snip>
chironvaccines.com |
